The onset of effect of the H1-antagonist acrivastine ("Semprex") assessed by histamine bronchial challenge in volunteers.
The onset of effect of acrivastine, a new H1-antagonist, has been assessed using antagonism of histamine-induced bronchoconstriction in sensitive volunteers. Acrivastine administered 30, 45, 60 or 90 min before challenge produced a right-shift of the histamine dose-response curve of at least 8-fold indicating that a clinically desired degree of H1-antagonism was present within 30 min of ingestion of the recommended therapeutic dose.
Rolan
P E
PE
Department of Clinical Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Phillips
S
S
Adams
J
J
Posner
J
J
D000284:Administration, Oral; D000328:Adult; D001980:Bronchi / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006632:Histamine; D006633:Histamine Antagonists / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008448:Maximal Expiratory Flow Rate / Q000187:drug effects; D014311:Triprolidine / Q000031:analogs & derivatives* / Q000494:pharmacology
D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D014311:Triprolidine; D006632:Histamine; C043648:acrivastine